Rapid Diagnosis of Drug Resistance to Fluoroquinolones, Amikacin, Capreomycin, Kanamycin and Ethambutol Using Genotype MTBDRsl Assay: A Meta-Analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Feng, Yan ^a   Liu, Sijun ^a   Wang, Qungang ^b   Wang, Liang ^c   Tang, Shaowen ^a   Wang, Jianming ^a   Lu, Wei ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Zhangjiagang Center for Disease Prevention and Control   (China)

^c EAST TENNESSEE STATE UNIVERSITY   (United States)

^d JIANGSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT SELECTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

AMIKACIN; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CAPREOMYCIN; DRUG RESISTANCE, BACTERIAL; ETHAMBUTOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FLUOROQUINOLONES; GENOTYPE; HUMANS; KANAMYCIN; LIKELIHOOD FUNCTIONS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; SENSITIVITY AND SPECIFICITY;

EID: 84873254065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055292     Document Type: Article

References (57)

1. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, et al. (2007) Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 13: 380-387.
2. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM (2007) First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 12: E070517 070511.
3. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, et al. (2007) Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis 13: 780-782.
4. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 136: 420-425.
5. WHO (2006) Emergence of XDR-TB.
6. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.
7. Raviglione M, (2006) XDR-TB: entering the post-antibiotic era? Int J Tuberc Lung Dis 10: 1185-1187.
8. Dorman SE, Chaisson RE, (2007) From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med 13: 295-298.
9. Garrigo M, Aragon LM, Alcaide F, Borrell S, Cardenosa E, et al. (2007) Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol 45: 1766-1770.
10. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC, (2006) International standards for tuberculosis care. Lancet Infect Dis 6: 710-725.
11. Shamputa IC, Rigouts, Portaels F, (2004) Molecular genetic methods for diagnosis and antibiotic resistance detection of mycobacteria from clinical specimens. APMIS 112: 728-752.
12. Pai M, Kalantri S, Dheda K, (2006) New tools and emerging technologies for the diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev Mol Diagn 6: 423-432.
13. WHO (2010) Policy Framework for Implementing New Tuberculosis Diagnostics.
14. Almeida Da Silva PE, Palomino JC, (2011) Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother 66: 1417-1430.
15. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, et al. (2010) Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 48: 2934-2939.
16. Lacoma A, Garcia-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, et al. (2012) GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 50: 30-36.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG, (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6: e1000097.
18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, et al. (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155: 529-536.
19. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A, (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6: 31.
20. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
21. Cochran WG, (1954) The combination of estimates from different experiments. Biometrics 10: 101-129.
22. Walter SD, (2002) Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 21: 1237-1256.
23. Hillemann D, Rusch-Gerdes S, Richter E, (2009) Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 47: 1767-1772.
24. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W, (2010) Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48: 1683-1689.
25. van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, et al. (2010) Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 48: 2749-2753.
26. Huang WL, Chi TL, Wu MH, Jou R, (2011) Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 49: 2502-2508.
27. Kontsevaya I, Mironova S, Nikolayevskyy V, Balabanova Y, Mitchell S, et al. (2011) Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and-multidrug-resistance Settings. J Clin Microbiol 49: 2832-2837.
28. Ignatyeva O, Kontsevaya I, Kovalyov A, Balabanova Y, Nikolayevskyy V, et al. (2012) Detection of resistance to second-line antituberculosis drugs by use of the genotype MTBDRsl assay: a multicenter evaluation and feasibility study. J Clin Microbiol 50: 1593-1597.
29. Miotto P, Cabibbe AM, Mantegani P, Borroni E, Fattorini L, et al. (2012) GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 40: 690-698.
30. Said HM, Kock MM, Ismail NA, Baba K, Omar SV, et al. (2012) Evaluation of the GenoType(R) MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 16: 104-109.
31. Tessema B, Beer J, Emmrich F, Sack U, Rodloff AC, (2012) Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 12: 37.
32. WHO (2011) Tuberculosis MDR-TB & XDR-TB 2011 preogress report.
33. Heysell SK, Houpt ER, (2012) The future of molecular diagnostics for drug-resistant tuberculosis. Expert Rev Mol Diagn 12: 395-405.
34. Muyoyeta M, Schaap JA, De Haas P, Mwanza W, Muvwimi MW, et al. (2009) Comparison of four culture systems for Mycobacterium tuberculosis in the Zambian National Reference Laboratory. Int J Tuberc Lung Dis 13: 460-465.
35. Palomino JC, (2012) Current developments and future perspectives for TB diagnostics. Future Microbiol 7: 59-71.
36. Gallagher EJ, (1998) Clinical utility of likelihood ratios. Ann Emerg Med 31: 391-397.
37. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM, (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56: 1129-1135.
38. Jaeschke R, Guyatt GH, Sackett DL, (1994) Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 271: 703-707.
39. Wang JC, (1996) DNA topoisomerases. Annu Rev Biochem 65: 635-692.
40. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, et al. (1994) Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 38: 773-780.
41. Drlica K, (1999) Mechanism of fluoroquinolone action. Curr Opin Microbiol 2: 504-508.
42. Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, et al. (2004) Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 48: 596-601.
43. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, et al. (2008) Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents 31: 115-121.
44. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, et al. (1998) Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1295-1297.
45. Suzuki Y, Katsukawa C, Tamaru A, Abe C, Makino M, et al. (1998) Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J Clin Microbiol 36: 1220-1225.
46. Maus CE, Plikaytis BB, Shinnick TM, (2005) Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 49: 3192-3197.
47. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, et al. (2012) Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7: e33275.
48. Kruuner A, Jureen P, Levina K, Ghebremichael S, Hoffner S, (2003) Discordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 2971-2973.
49. Zaunbrecher MA, Sikes RD Jr, Metchock B, Shinnick TM, Posey JE, (2009) Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 106: 20004-20009.
50. Gikalo MB, Nosova EY, Krylova LY, Moroz AM, (2012) The role of eis mutations in the development of kanamycin resistance in Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother 67: 2107-2109.
51. Sreevatsan S, Stockbauer KE, Pan X, Kreiswirth BN, Moghazeh SL, et al. (1997) Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob Agents Chemother 41: 1677-1681.
52. Isola D, Pardini M, Varaine F, Niemann S, Rusch-Gerdes S, et al. (2005) A Pyrosequencing assay for rapid recognition of SNPs in Mycobacterium tuberculosis embB306 region. J Microbiol Methods 62: 113-120.
53. Ahmad S, Jaber AA, Mokaddas E, (2007) Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinb) 87: 123-129.
54. Hazbon MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, et al. (2005) Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother 49: 3794-3802.
55. Plinke C, Cox HS, Kalon S, Doshetov D, Rusch-Gerdes S, et al. (2009) Tuberculosis ethambutol resistance: concordance between phenotypic and genotypic test results. Tuberculosis (Edinb) 89: 448-452.
56. Scarparo C, Ricordi P, Ruggiero G, Piccoli P, (2004) Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J Clin Microbiol 42: 1109-1114.
57. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL, (2011) Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis 15: 116-124.